Patent · US Active

Antibodies against epidermal growth factor receptor (EGFR) and uses thereof

US10072299B2 · kind B2 · utility

0Cited by

16References

21Claims

0Family size

Assignee

Merrimack Pharmaceuticals, Inc. · US

Inventors

Raghida BUKHALID · Melrose, US
Michael Feldhaus · Lebanon, US
Anne Richard · Cambridge, US
Neeraj Kohli · Watertown, US
Eric Krauland · Lebanon, US
Jeffrey David KEARNS · Arlington, US
Alexey A. Lugovskoy · Woburn, US
Ulrik Nielsen · Quincy, US

Key dates

Filing date	Sep 8, 2015
Grant date	Sep 11, 2018
Priority date	—
Expiry date	Aug 14, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.